We stand with Ukraine!
Bücher für Medizin, Wissenschaft und Studium

This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry.

Section One Hormone Therapy
Chapter 1 Cell Biology of Prostate Cancer and Molecular Targets
Martin E. Gleave, Michael E. Cox, Yuzhuo Wang
Chapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer
Andrew V. Schally and Norman L. Block
Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer
Hannelore V. Heemers and Donald J. Tindall
Chapter 4 Androgens and Prostate Cancer
Douglas K. Price and Ann W. Hsing
Chapter 5 Androgen Receptor Biology in Prostate Cancer
Edward P. Gelmann
Chapter 6 Androgen Receptor Antagonists
Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk
Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer
Zoran Culig
Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer
Terence W. Friedlander and Charles J. Ryan
Chapter 9 Androgen Deprivation Therapy
Nima Sharifi
Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway
Francine Zanchetta Coehlo Marques and Juergen Reichardt
Section Two Chemotherapy
Chapter 11 Mitoxantrone
Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr.
Chapter 12 Docetaxel
Courtney K. Phillips and Daniel P. Petrylak
Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
Jonathan Rosenberg
Chapter 14 Platinum Agents in Prostate Cancer
Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh
Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer
Tristan M. Sissung and William D. Figg
Chapter 16 Microtubule Targeting Agents
Antonio Tito Fojo and David E. Adelberg
Section Three Angiogenesis
Chapter 17 Principles of Antiangiogenic Therapy
Cindy H. Chau and William D. Figg
Chapter 18 Bevacizumab in Advanced Prostate Cancer
Aymen A. Elfiky and William Kevin Kelly
Chapter 19 Thalidomide and Analogs
Erin R. Gardner, Giuseppe Di Lorenzo, and William D. Figg
Chapter 20 Investigational Angiogenesis Inhibitors
Jeanny B. Aragon-Ching, William Dahut, MD
Chapter 21 Pharmacogenetics of Angiogenesis
Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi
Section Four Bone Metastasis
Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis
Evan T. Keller and Christopher L. Hall
Chapter 23 Radiopharmaceuticals
Oliver Sartor and Damerla R. Venugopal
Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases
Philip J. Saylor and Matthew R. Smith
Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer
Joel B. Nelson
Chapter 26 Calcitriol and Vitamin D Analogs
Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas
Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches
Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom
Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer
Celestia S. Higano and Mark W. Frohlich
Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX
Lalit R. Patel and Jonathan W. Simons
Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment
Andrea L. Harzstark and Lawrence Fong
Section Five ? Prevention
Chapter 31 Prostate Cancer Chemoprevention Strategies
Howard L. Parnes, Margaret G. House, Joseph A. Tangrea
Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk
June M. Chan and Erin L. Richman
Chapter 33 Inflammation as a Target in Prostate Cancer
Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo
Section Six Drug Development
Chapter 34 Challenges for the Development of New Agents in Prostate Cancer
Ajjai S. Alva, Deborah A. Bradley, Maha Hussain
Chapter 35 FDA Approval of Prostate Cancer Treatments
Yang-Min Ning, Ramzi N. Dagher, Richard Pazdur
Chapter 36 Applications of Proteomics in Prostate Cancer
Mitchell Gross, Edward Macrohon Nepomuceno, David B. Agus